Inrig Jula's Form 4 filing
Travere Therapeutics, Inc. (TVTX) · filed Jan 5, 2024
- Accession no.
- 0001209191-24-001005
- Filed
- Jan 5, 2024
- Trade date
- Jan 3-4, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market sales total $23.6K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Inrig JulaCIK 0001902368 | Officer (Chief Medical Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 3, 2024 | Common Stock | SSaleDisposed | −2,069 | $9.48 | −$19,614.12 | 35,688 | Direct | |
| Jan 4, 2024 | Common Stock | SSaleDisposed | −440 | $9.17 | −$4,034.8 | 35,248 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.